Boundless Bio, Inc.

The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit

Lykos Therapeutics , still reeling from US Food and Drug Administration rejection of the company’s capsule formulation of the psychedelic drug midomafetamine for the treatment of post-traumatic stress

US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w

Biopharmaceutical companies have raised one venture capital mega-round after another in 2024 – with several of the $100m-plus financings often announced on the same day – and first quarter VC fundrais